A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach Meeting Abstract
| Authors: | Dorsey, C.; Falco, V.; Pena-Velasquez, C.; Lebowitz, S.; Purdom, M.; Panton, G. |
| Abstract Title: | A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach |
| Meeting Title: | 47th Annual Congress of the Oncology Nursing Society (ONS) |
| Journal Title: | Oncology Nursing Forum |
| Volume: | 49 |
| Issue: | 2 |
| Meeting Dates: | 2022 Apr 27-May 1 |
| Meeting Location: | Anaheim, CA |
| ISSN: | 0190-535X |
| Publisher: | Oncology Nursing Society (ONS) |
| Date Published: | 2022-03-01 |
| Start Page: | E3 |
| Language: | English |
| ACCESSION: | WOS:000790312800447 |
| PROVIDER: | wos |
| DOI: | 10.1188/22.ONF.E3 |
| Notes: | Meeting Abstract: P303 -- Found in PDF named "2022 ONS Congress Late-Breaking Abstracts" -- on p.48 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work